- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
5′ ALK Amplification in Neuroblastoma: A Case Report ; volume:14 ; number:1 ; year:2021 ; pages:585-591 ; extent:7
Case reports in oncology ; 14, Heft 1 (2021), 585-591 (gesamt 7)
- Urheber
-
Akhavanfard, Sara
Nohr, Erik
AlNajjar, Mohammad
Haughn, Mollie
Hashimoto, Sayaka
Deeg, Carol
Pfau, Ruthann
Brundler, Marie-Anne
Reshmi, Shalini C.
- DOI
-
10.1159/000512187
- URN
-
urn:nbn:de:101:1-2021051301003056405646
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Akhavanfard, Sara
- Nohr, Erik
- AlNajjar, Mohammad
- Haughn, Mollie
- Hashimoto, Sayaka
- Deeg, Carol
- Pfau, Ruthann
- Brundler, Marie-Anne
- Reshmi, Shalini C.
Ähnliche Objekte (12)
Towards optimizing combination therapy in ALK-positive neuroblastoma
Mechanistic insights into ALK inhibitor resistance in neuroblastoma
ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
Subfrontal Schwannoma Mimicking Neuroblastoma: Case Report
Targeted therapy of neuroblastoma with HDAC8 inhibitor and ALK inhibitor
DDX1 co-amplification confers collateral vulnerabilities in neuroblastoma
First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report
Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma
MYCN amplification in neuroblastoma: sequence, chromatin landscape, and genome remodeling
Malakoplakia with aberrant ALK expression by immunohistochemistry: a case report
Towards optimizing combination therapy in ALK-positive neuroblastoma
Mechanistic insights into ALK inhibitor resistance in neuroblastoma
ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
Subfrontal Schwannoma Mimicking Neuroblastoma: Case Report
Targeted therapy of neuroblastoma with HDAC8 inhibitor and ALK inhibitor
DDX1 co-amplification confers collateral vulnerabilities in neuroblastoma
First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report
Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma
MYCN amplification in neuroblastoma: sequence, chromatin landscape, and genome remodeling
Malakoplakia with aberrant ALK expression by immunohistochemistry: a case report
Towards optimizing combination therapy in ALK-positive neuroblastoma
Mechanistic insights into ALK inhibitor resistance in neuroblastoma
ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
Subfrontal Schwannoma Mimicking Neuroblastoma: Case Report
Targeted therapy of neuroblastoma with HDAC8 inhibitor and ALK inhibitor
DDX1 co-amplification confers collateral vulnerabilities in neuroblastoma
First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report
Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma
MYCN amplification in neuroblastoma: sequence, chromatin landscape, and genome remodeling